UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

[ X ]             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                  THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended September 30, 2000

                                       OR

[   ]             TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                  THE SECURITIES EXCHANGE ACT OF 1934

                  For the transition period from ____________ to ____________

                  Commission file number: 0-18271


                             BIOMERIDIAN CORPORATION
                           ---------------------------
             (Exact name of registrant as specified in its charter)

                                      Utah
                                     ------
         (State or other jurisdiction of incorporation or organization)

                                   87-0467614
                                  ------------
                      (I.R.S. Employer Identification No.)


                12411 South 265 West, Suite F, Draper, Utah 84020
               ---------------------------------------------------
                    (Address of principal executive offices)
                                   (Zip Code)

                                 (801) 501-7517
                                 ---------------
              (Registrant's telephone number, including area code)

                            Magellan Technology, Inc.
                -------------------------------------------------
         (Former Name, former address and former fiscal year, if changed
                               since last report)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes X No _____

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:

Number outstanding at September 30, 2000: 28,826,997 shares
Class:                              Common Stock, $.0002 par value



<PAGE>


                                   FORM 10-QSB

                       Financial Statements and Schedules
                             BioMeridian Corporation

                    For the Quarter Ended September 30, 2000

The  following  financial  statements  and schedules of the  registrant  and its
consolidated subsidiaries are submitted herewith:


                         PART I - FINANCIAL INFORMATION
                        --------------------------------
Item 1.  Financial Statements

             Condensed consolidated balance sheet for September 30, 2000    3

             Condensed consolidated statement of operations for the three
             months and nine months ended September 30, 2000 and 1999       4

             Condensed statement of cash flows for the nine months ended
             September 30, 2000 and 1999                                    5

             Notes to condensed consolidated financial statements           7

Item 2.      Management's Discussion and Analysis of Financial Condition
             and Results of Operations                                      9


                           PART II - OTHER INFORMATION
                          -----------------------------
Item 1.  Legal Proceedings                                                  11

Item 2.  Changes in Securities                                              11

Item 3.  Defaults upon Senior Securities                                    11

Item 4.  Submission of Matters to a Vote of Security Holders                11

Item 5.  Other information                                                  11

Item 6(a)         Exhibits                                                  11

Item 6(b)         Reports on Form 8-K                                       11

<PAGE>
                           BIOMERIDIAN CORPORATION
                              AND SUBSIDIARIES

                    Condensed Consolidated Balance Sheets


                                                                   30-Sep-00
                                   ASSETS                        (Unaudited)
                                                               -------------
Current Assets:
 Cash                                                               $ 39,139
 Accounts Receivable, net                                          1,415,396
 Investment in Securities                                          1,600,000
 Inventories                                                         143,268
 Prepaid Expenses                                                     21,436
 Other Current Assets                                                 39,647
                                                               -------------
   Current Assets                                                  3,258,886
                                                               -------------

 Property and Equipment, net                                         230,400
 Goodwill, net                                                       444,517
 Licenses & Technology, net                                        1,094,922
                                                               -------------
   Total Assets                                                   $5,028,725
                                                               =============
                                 LIABILITIES

Current Liabilities:
 Accounts Payable                                                  $ 677,280
 Accrued Personnel Costs                                             109,557
 Accrued Liabilities                                                 281,113
 Accrued Interest Payable                                            298,879
 Note Payable                                                      1,296,158
 Related Party Notes Payable                                       1,611,048
 Current Portion of long-term debt                                   368,175
                                                               -------------
   Current Liabilities                                             4,642,210

 Long-Term Debt                                                       27,525
                                                               -------------
   Total Liabilities                                               4,669,735
                                                               -------------
                            STOCKHOLDERS' EQUITY

 Common Stock, par value $.0002 per share;
   50,000,000 shares authorized, 28,826,997 shares
   issued and outstanding as of September 30, 2000                     5,765
 Additional Paid-in Capital                                       14,747,954
 Accumulated Deficit                                             (14,394,729)
                                                               -------------
   Total Stockholders' equity                                        358,990
                                                               -------------
     Total Liabilities and Stockholders' Equity                   $5,028,725
                                                               =============

<PAGE>
<TABLE>
<CAPTION>

                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

                 Condensed Consolidated Statements of Operations
                                   (Unaudited)
                                                                  Three Months                      Nine Months
                                                               Ended September 30               Ended September 30
                                                              2000             1999            2000             1999
                                                         -------------    -------------   -------------    -------------
<S>                                                         <C>             <C>              <C>             <C>
 Net Sales                                                  $1,441,819      $1,943,504       $4,774,099      $5,616,425
 Cost of Sales                                                 134,077         220,850          631,259         895,909
                                                         -------------    -------------   -------------    -------------
   Gross Margin                                              1,307,742       1,722,654        4,142,840       4,720,516

 Variable Selling Costs                                        211,475         315,303          648,835       1,094,218
                                                         -------------    -------------   -------------    -------------
   Contribution Margin                                       1,096,267       1,407,350        3,494,005       3,626,298

Operating Expenses:
 Administration & Finance                                      313,890         336,096        1,044,672         967,702
 Customer Support                                               29,317          34,377          103,005         138,996
 Marketing                                                     105,462               -          189,532               -
 Operations & Engineering                                      123,540         112,583          332,757         354,755
 Sales - Domestic                                              251,618         440,489          757,690       1,608,069
 Sales - International                                          52,996         109,340          165,480         217,441
 Training & Education                                          147,899         178,985          399,356         539,687
 Depreciation Expense                                           17,158          14,486           48,214          42,058
 Amortization of Licenses & Goodwill                           156,073         156,073          468,218         464,703
                                                         -------------    -------------   -------------    -------------
    Total Operating Expenses                                 1,197,953       1,382,430        3,508,924       4,333,410
                                                         -------------    -------------   -------------    -------------
 Income/(Loss) from Operations                                (101,686)         24,921          (14,919)       (707,112)

 Other (Income)/Expense:
 Other (Income)/Expense                                       (148,000)         (1,086)        (162,194)         (1,952)
 Interest Expense                                              106,180         147,434          346,499         465,643
                                                         -------------    -------------   -------------    -------------
    Net Income/(Loss) before Discontinued Operations           (59,866)       (121,427)        (199,224)     (1,170,803)
 Loss from Discontinued Operations                                             370,035                          847,211
                                                         -------------    -------------   -------------    -------------
    Net Income/(Loss) before Income Taxes                      (59,866)       (491,462)        (199,224)     (2,018,014)
 Provision for Income Taxes
                                                         -------------    -------------   -------------    -------------
    Net Income/(Loss)                                        $ (59,866)     $ (491,462)      $ (199,224)   $ (2,018,014)
                                                         =============    =============   =============    =============

    Net Income/(Loss) per share                                $ (0.00)        $ (0.02)         $ (0.01)        $ (0.09)
                                                         =============    =============   =============    =============

 Weighted average shares outstanding                        27,811,085      22,329,973       27,811,085      22,329,973
                                                         =============    =============   =============    =============

</TABLE>
<PAGE>
<TABLE>
<CAPTION>
                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)
                                                                             Nine Months
                                                                          Ended September 30
                                                                          2000             1999
Cash Flows from Operating Activities:                                -------------    -------------
<S>                                                                     <C>            <C>
 Net Income/(Loss) from continuing operations                           $ (199,224)    $ (1,559,514)
 Adjustments to Reconcile Net Income/(Loss)
   to Net Cash used in Operating Activities:
     Provision for Bad Debt                                                (66,440)          18,400
     Stock Compensation                                                                      45,362
     Issuance of common stock for services                                  51,000           35,000
     Forgiveness of debt                                                                   (458,500)
     Depreciation Expense                                                   48,214           42,058
     Amortization of Licenses & Goodwill                                   468,218          464,703
     (Gain)/Loss on sale of assets                                                              151
     Net assets of discontinued operations                                                  153,211
 (Increase)/Decrease in:
   Accounts Receivable                                                    (229,491)        (526,919)
   Inventory                                                                (7,537)         155,076
   Prepaid Expenses and other assets                                       (15,409)         (28,738)
 Increase/(Decrease) in:
   Accounts Payable                                                       (139,334)         (48,774)
   Accrued Personnel Costs                                                  24,171          (53,099)
   Accrued Liabilities                                                      29,636          207,052
   Accrued Interest Payable                                                 78,338          147,858
                                                                     -------------    -------------
 Net Cash Provided by/(Used in) Operating Activities                        42,142       (1,406,673)
                                                                     -------------    -------------
Cash Flows from Investing Activities:
 Purchase of Property & Equipment                                          (48,655)         (45,031)
 Notes Receivable                                                          900,000
 Sale of Property & Equipment                                                                 3,804
                                                                     -------------    -------------
 Net Cash Provided by/(Used in) Investing Activities                       851,345          (41,227)
                                                                     -------------    -------------
Cash Flows from Financing Activities:
 Issuance of Common Stock                                                                   311,838
 Proceeds from Related Party Notes                                       1,032,899          640,000
 Principal Payments on Related Party Notes                                (192,899)        (345,000)
 Proceeds from Notes Payable                                                              1,000,000
 Principal Payments on Notes Payable                                    (1,200,000)         (45,000)
 Proceeds from Line of Credit                                                                13,843
 Principal Payments on Line of Credit                                                       (50,000)
 Proceeds from Long-term Debt                                                                18,798
 Principal Payments on Long-term Debt                                     (774,547)         (88,067)
                                                                     -------------    -------------
 Net Cash Provided by/(Used in) Financing Activities:                   (1,134,547)       1,456,412
                                                                     -------------    -------------
 Net Decrease in cash                                                     (241,060)           8,512

 Cash, Beginning of Period                                                 280,199          155,617
                                                                     -------------    -------------
 Cash, End of Period                                                      $ 39,139        $ 164,129
                                                                     =============    =============
</TABLE>
<PAGE>

                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)


                                                     Nine Months
                                                  Ended September 30
                                                2000             1999
Cash paid during the period for:           -------------    -------------

 Interest                                      $ 268,161        $ 236,079
                                           =============    =============

 Income Taxes                                        $ -              $ -
                                           =============    =============

2000 Non-cash Financing and Investing Activities:

  During the nine months ended September 30, 2000, the company converted accrued
interest  payable to a shareholder  and director to a note payable in the amount
of $98,048.

  During the nine months ended  September 30, 2000,  the company  issued 100,000
and 2,000 shares of common stock for services to individuals.

  During the nine months  ended  September  30,  2000,  the Company  applied the
remaining  balance of a note  payable to an entity to accounts  receivable  from
that entity in the amount of $4,510.

  During the nine months ended September 30, 2000, the Company  exchanged a note
receivable  due from an entity of $1,600,000  for 290,909 shares of the entity's
preferred stock. (see note 4)

  During the nine months ended September 30, 2000, the Company converted   notes
payable to a director of the Company and an entity owned by a director  totaling
$500,000 in exchange for 1,250,000 shares of the Company's common stock.

  During the nine months  ended  September  30, 2000,  the Company  purchased an
asset in exchange for a capital lease of $24,121.

1999 Non-Cash Financing and Investing Activities:

  During the nine months ended September 1999, the Company converted  $1,900,000
of notes payable and $11,033 of accrued interest payable into common stock.

  During the nine months ended  September 30, 1999,  the Company  issued 250,000
shares of common stock in exchange for the rights to certain technology known as
the P.I.C.E. Technology. The value of this transaction was $140,625.

  During the nine months ended September 30, 1999, the Company converted certain
accounts  payable  balances  to certain  vendors to a note  payable.  The amount
converted was $23,769.

  During the nine months  ended  September  30, 1999,  the Company  converted an
accounts payable balance to a certain vendor to common stock and a note payable.
The amount converted was $25,000 and $39,313 respectively.

  During the nine months  ended  September  30,  1999,  the  Company  applied an
accounts  receivable  balance  from a  customer  in the amount of $47,600 to the
outstanding amount of a note payable to this same individual.

<PAGE>

                             BIOMERIDIAN CORPORATION
                                AND SUBSIDIARIES

              Notes to Condensed Consolidated Financial Statements

1)   The  unaudited  condensed  consolidated  financial  statements  include the
     accounts of BioMeridian  Corporation.  (The "Company") and its wholly owned
     subsidiaries,  BioMeridian  Corporation [formerly known as ProHealth,  Inc.
     and prior to that known as Satellite  Image Systems,  Inc. (SIS,  Inc.) and
     SIS  Jamaica,   LTD  (SIS  Jamaica)],   BioMeridian   International,   Inc.
     ("BioMeridian") (formerly known as BioSource,  Inc.) and Bio-Origins,  Inc.
     ("Bio-Origins").  On February 16, 1999, the Company acquired certain assets
     known as the P.I.C.E. technology from an individual in exchange for 250,000
     shares of  common  stock.  In  September  1999 the  Company  completed  the
     acquisition of Biological Technologies International,  Inc. (BTI) which the
     Company  acquired  effective  September  17, 1999 through its  wholly-owned
     subsidiary  BTI  Acquisition  Corp.  The  acquisition  of BTI  included the
     issuance  of  3,024,024  shares  of  Magellan  common  stock for all of the
     outstanding  shares of BTI common stock.  The acquisition was accounted for
     as a "pooling of interests" transaction.

2)   The  unaudited  condensed  consolidated  financial  statements  include all
     adjustments,  consisting  of normal  recurring  items,  which  are,  in the
     opinion of management,  necessary to present fairly the financial  position
     of the Company as of September 30, 2000 and the results of  operations  for
     the three months and nine months ended September 30, 2000 and 1999 and cash
     flows for the nine months ended September 30, 2000 and 1999. The results of
     operations  for  the  three  months  ended   September  30,  2000  are  not
     necessarily  indicative  of  quarterly  results  to  be  expected  for  the
     remainder of the year.

3)   The amount of the loss per share is based on the weighted average number of
     shares outstanding at September 30, 2000 and 1999, respectively.


4)   Effective December 31, 1999, the Company completed the disposition and sale
     of SkyHook Technologies, Inc. to Envirofoam Technologies, Inc. ("EFT"). The
     sale was completed in exchange for $3,000,000.  Of this sale amount, a note
     payable was issued by EFT in the amount of $2,500,000  and a management fee
     for  services  rendered  in the  amount  of  $500,000  would be paid to the
     Company.  On the closing date of this sale  transaction,  $500,000 was paid
     and received  against the note  payable and the  remaining  $2,000,000  was
     originally  intended  to be paid in four  consecutive  payments of $500,000
     over the next four months,  with the first payment due on or before January
     31,  2000.  On March 9,  2000,  the  terms of  repayment  of the note  were
     amended.  The  January  31,  2000  payment  was  received  in the amount of
     $500,000  and the  remaining  balance was  intended  to be received  over 3
     monthly  payments  in the  amounts  of  $100,000,  $500,000  and  $900,000,
     respectively,  beginning  March 31, 2000.  The  management  fee of $500,000
     remained  due and payable on or before May 31,  2000.  On May 5, 2000,  the
     terms of  repayment  of the note were  again  amended.  The March 31,  2000
     payment was  received in the amount of $100,000 and a payment in the amount
     of  $300,000  was  received  on April 30,  2000  leaving a total  remaining
     balance due of $1,600,000.  Effective June 30, 2000, this remaining balance
     due was converted to 290,909  shares of EFT Series B Convertible  Preferred
     Stock.  As interest  payments,  EFT is  obligated to issue to the Company a
     specified  number of additional  shares of Series B  Convertible  Preferred
     Stock at the end of each of the next eleven  months  beginning  on July 31,
     2000 if all of these preferred shares have not been sold by the Company.

5)   On May 19, 1998 the Company  entered  into a $3,000,000  revolving  line of
     credit   agreement.   Obligations  under  prior  separate  line  of  credit
     agreements  for $750,000 and $745,000  were retired with  proceeds from the
     new revolving line of credit. During the six months ended June 30, 1999 the
     Company made no additional  borrowings under this revolving line of credit.
     This  revolving  line of credit is secured by the  Company's  inventory and
     receivables and by the personal guarantees of the Company's Chief Executive
     Officer, a director,  and a major  shareholder.  On December 15, 1999, this
     line of credit was  converted to a term loan whereby 5 monthly  payments in
     the amount of $500,000 commencing December 31, 1999 and concluding on April
     30, 2000  followed by a final  payment of $496,158 on May 31, 2000 would be
     made.  On May 22, 2000, a  modification  agreement was entered into whereby
     the  monthly  payments  to be  received  pursuant  to this  term  loan were
     changed. Under the new agreement,  three payments in the amount of $100,000
     each  followed by one in the amount of $1,196,158  commencing  May 31, 2000
     would  replace the monthly  payments  under the previous  agreement.  As of
     September 30, 2000 the Company had an outstanding  balance of $1,296,158.33
     under this term loan. The Company is current in its obligations  under this
     loan.

6)   During the nine months ended September 30, 2000, the Company borrowed a net
     amount of $840,000  from the Company's  Chief  Executive  Officer,  or from
     entities  controlled  by this  individual,  under three  separate  $100,000
     unsecured  note  payable  agreements,  one $40,000  unsecured  note payable
     agreement,  two $50,000  unsecured  note payable  agreements,  one $150,000
     unsecured note payable  agreement,  and one $250,000 unsecured note payable
     agreement.  Each note  payable  bears  interest at 12% and is payable  upon
     demand. Interest has been accrued, but unpaid and the outstanding principal
     and interest payable totals $1,390,328 at September 30, 2000.

7)   During the nine months ended  September 30, 2000,  the Company paid $40,000
     in consulting expense to an entity controlled by an officer of the Company.
     The company also paid consulting  expense to a shareholder in the amount of
     $18,333.

8)   On October 16, 2000, the Company  entered into an agreement to sell certain
     assets  to a  related  party,  including  certain  intangibles,  valued  at
     $578,000 in  exchange  for a  forgiveness  of a note  payable of  $338,000,
     accrued  interest  of  $125,000,  and  a  technology  license  and  product
     distribution rights.




<PAGE>


                         PART I - FINANCIAL INFORMATION


Item 2.           Management's Discussion and Analysis of Financial Condition
                  and Results of Operations

Nine-month  period ended  September 30, 2000 compared to the  Nine-month  period
ended September 30, 1999.

The BioMeridian  Corporation  mission is to develop and market  state-of-the-art
methods for delivering  integrative  healthcare to the marketplace.  BioMeridian
manufactures and sells the MSA/IMAG and BEST systems to healthcare practitioners
throughout  the  world.  This  equipment  is used to assess  stress  and  assist
healthcare practitioners in the analysis and treatment of certain conditions. If
stress  or  imbalance  is  detected  in  a  patient,   the  systems  assist  the
practitioner  in  recommending a course of treatment or therapy to alleviate the
stress or to restore balance to the body's meridian  systems.  BioMeridian  also
provides  training  classes and support  services for health care  practitioners
that utilize these systems. The MSA/IMAG system is registered with the U.S. Food
and Drug Administration as a stress-monitoring device.

Beginning  January 1, 2000, the operations of BioMeridian  and BTI were combined
and integrated  into the Company.  For the nine months ended September 30, 2000,
the Company  achieved sales revenues of $4,774,099,  which resulted in operating
loss of $14,919,  compared with sales revenues of $5,616,425,  which resulted in
an operating loss of $707,112 for the nine months ended  September 30, 1999. The
decrease  in sales was the result of the  transition  process  from  independent
sales  representatives to hiring and training several new sales personnel within
the  Company.  The  decrease in  operating  loss was  primarily  due to slightly
improved margins and substantially reduced costs. Most notably,  during the nine
months ended September 30, 2000 approximately $660,000 less expense was incurred
for domestic  selling  expenses  verses the same period in 1999 when  additional
personnel and travel-related expenses were incurred.

Three-month  period ended September 30, 2000 compared to the three-month  period
ended September 30, 1999.

For the three  months  ended  September  30, 2000,  the Company  achieved  sales
revenues  of  $1,441,819,  which  resulted  in an  operating  loss of  $101,686,
compared with sales revenues of $1,943,504,  which resulted in operating  income
of $24,921 for the three months ended  September 30, 1999. The decrease in sales
was the result of the transition process from independent sales  representatives
to hiring and training several new sales personnel  within the Company.  Expense
containment  resulted  in  operating  expenditures  for the three  months  ended
September 30, 2000 of approximately  $185,000 less than those of the same period
in the prior  year.  However,  lower  gross  margin  dollars on lower  sales (as
discussed  above) for the 3-months  ended  September 30, 2000  accounted for the
increase in operating loss for the period.

Liquidity and Capital Resources

On May 19, 1998 the Company  entered into a $3,000,000  revolving line of credit
agreement.  Obligations  under  prior  separate  line of credit  agreements  for
$750,000 and $745,000 were retired with proceeds from the new revolving  line of
credit.  During the nine months  ended  September  30, 2000 the Company  made no
additional  borrowings  under  a  $3,000,000  revolving  line  of  credit.  This
revolving line of credit is secured by the Company's  inventory and  receivables
and by the personal  guarantees  of the Company's  Chief  Executive  Officer,  a
director, and a major shareholder. On December 15, 1999, this line of credit was
converted  to a term loan  whereby 5 monthly  payments in the amount of $500,000
commencing  December  31, 1999 and  concluding  on April 30, 2000  followed by a
final  payment of  $496,158 on May 31, 2000 would be made.  On May 22,  2000,  a
modification  agreement  was entered  into  whereby  the monthly  payments to be
received pursuant to this term loan were changed. Under the new agreement, three
payments  in the  amount  of  $100,000  each  followed  by one in the  amount of
$1,196,158  commencing May 31, 2000 would replace the monthly payments under the
previous  agreement.  As of  September  30, 2000 the Company had an  outstanding
balance of  $1,296,158.33  under this term loan.  The  Company is current in its
obligations under this loan.

During the nine months  ended  September  30, 2000,  the Company  borrowed a net
amount of $840,000 from the Company's Chief Executive Officer,  or from entities
controlled by this  individual,  under three  separate  $100,000  unsecured note
payable  agreements,  one $40,000 unsecured note payable agreement,  two $50,000
unsecured  note  payable   agreements,   one  $150,000  unsecured  note  payable
agreement, and one $250,000 unsecured note payable agreement.  Each note payable
bears interest at 12% and is payable upon demand. Interest has been accrued, but
unpaid and the outstanding  principal and interest payable totals  $1,390,328 at
September 30, 2000.


<PAGE>


                           PART II - OTHER INFORMATION

Item 1.  Legal proceedings:

                  The Company is party to one proceeding, which is considered by
                  Management  to  be  routine   litigation   incidental  to  the
                  business, and which is not product related.

Item 2.  Changes in Securities:     None.

Item 3.  Defaults upon Senior Securities:   None.

Item 4.  Submission of Matters to a Vote of Security Holders: None.

Item 5.  Other information: None.

Item 6.  Exhibits and Reports on Form 8-K

                  A report on Form 8-K, which reported the Company's name change
                  from Magellan Technology,  Inc. to BioMeridian Corporation and
                  also the new trading symbol of "BIDN"  (replacing  "MGLN") for
                  the Company's common stock, was filed on August 21, 2000.


<PAGE>


SIGNATURES

In accordance with the  requirements of the Exchange Act, the registrant  caused
this  report to be  signed on its  behalf  by the  undersigned,  thereunto  duly
authorized.


                             BIOMERIDIAN CORPORATION
                            -------------------------
                                  (Registrant)




\s\William A. Fresh                                           November 15, 2000
------------------------                                      -----------------
William A. Fresh                                              Date
Chairman and Chief Executive Officer